Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Sell
7
PMVP Quote, Financials, Valuation and Earnings
Last price:
$1.37
Seasonality move
:
-27.93%
Day range:
$1.33 - $1.40
52-week range:
$1.32 - $2.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.36x
Volume:
142.6K
Avg. volume:
211.8K
1-year change:
-32.84%
Market cap:
$70.9M
Revenue:
--
EPS (TTM):
-$1.00
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, PMV Pharmaceuticals has 323.36% upside to fair value with a price target of -- per share.
PMVP vs. S&P 500
-
Over the past 5 trading days, PMV Pharmaceuticals has underperformed the S&P 500 by -10.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PMV Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PMV Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PMV Pharmaceuticals reported revenues of --.
Earnings Growth
-
PMV Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PMV Pharmaceuticals reported earnings per share of -$0.37.
Enterprise value:
-111.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$74.4M | -$82.4M | -$79.2M | -$19.6M | -$21.9M | |
| EBITDA | -$74M | -$81.4M | -$77.7M | -$19.3M | -$21.5M | |
| Diluted EPS | -$1.59 | -$1.57 | -$1.00 | -$0.34 | -$0.37 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $373.7M | $313.6M | $265.2M | $205.3M | $189.6M | |
| Total Assets | $374.4M | $344.2M | $285M | $261M | $223.5M | |
| Current Liabilities | $5.5M | $8.6M | $11.7M | $10.7M | $13.6M | |
| Total Liabilities | $5.5M | $19.2M | $23.8M | $23.4M | $25.6M | |
| Total Equity | $369M | $324.9M | $261.2M | $237.6M | $197.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.5M | -$58.9M | -$46.7M | -$15.7M | -$16.8M | |
| Cash From Investing | -$17M | -$24.7M | $43M | -$33.6M | $17.1M | |
| Cash From Financing | $705K | $35.8M | $429K | $33.1M | -- | |
| Free Cash Flow | -$67.1M | -$61.3M | -$47.5M | -$15.7M | -$16.8M | |
PMVP
Sector
Market Cap
$70.9M
$45.4M
Price % of 52-Week High
60.62%
46.67%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-32.84%
-33.9%
Beta (5-Year)
--
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.45
200-day SMA
Sell
Level
$1.63
Bollinger Bands (100)
Sell
Level
1.48 - 1.64
Chaikin Money Flow
Sell
Level
-36.7M
20-day SMA
Sell
Level
$1.48
Relative Strength Index (RSI14)
Sell
Level
33.57
ADX Line
Sell
Level
25.41
Williams %R
Buy
Level
-83.3666
50-day SMA
Sell
Level
$1.57
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-4.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Stock Forecast FAQ
In the current month, PMVP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PMVP average analyst price target in the past 3 months is --.
-
Where Will PMV Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that PMV Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About PMV Pharmaceuticals?
Analysts are divided on their view about PMV Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PMV Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is PMV Pharmaceuticals's Price Target?
The price target for PMV Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PMVP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PMV Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PMVP?
You can purchase shares of PMV Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PMV Pharmaceuticals shares.
-
What Is The PMV Pharmaceuticals Share Price Today?
PMV Pharmaceuticals was last trading at $1.37 per share. This represents the most recent stock quote for PMV Pharmaceuticals. Yesterday, PMV Pharmaceuticals closed at $1.37 per share.
-
How To Buy PMV Pharmaceuticals Stock Online?
In order to purchase PMV Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Stanley Druckenmiller Buying Citigroup?
As recently as 2020, few analysts could have predicted that…
Where Does Cem Karsan Think the Market Is Headed in 2025?
Cem Karsan, the founder and managing partner of Kai Volatility…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Buy
71
SYM alert for Jan 17
Symbotic [SYM] is up 18.83% over the past day.
Sell
45
NUTX alert for Jan 17
Nutex Health [NUTX] is up 15.26% over the past day.
Buy
53
QMCO alert for Jan 17
Quantum [QMCO] is up 15.13% over the past day.
